{"id":565847,"date":"2026-09-28T00:30:00","date_gmt":"2026-09-27T22:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=565847"},"modified":"2026-09-26T23:09:45","modified_gmt":"2026-09-26T21:09:45","slug":"la-dapagliflozina-un-inhibidor-de-la-sglt-2-como-tratamiento-complementario-al-bloqueo-del-sra","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/es\/la-dapagliflozina-un-inhibidor-de-la-sglt-2-como-tratamiento-complementario-al-bloqueo-del-sra\/","title":{"rendered":"La dapagliflozina, un inhibidor de la SGLT-2, como tratamiento complementario al bloqueo del SRA"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>El amplio espectro de efectos terap\u00e9uticos de los inhibidores de SGLT-2 (cotransportador de sodio-glucosa tipo 2) abarca, entre otros, la protecci\u00f3n cardiorrenal en pacientes con enfermedad renal cr\u00f3nica (ERC) no diab\u00e9tica, tal y como demuestran de manera contundente los grandes ensayos cl\u00ednicos aleatorizados (ECA) realizados en adultos (por ejemplo, DAPA-CKD, EMPA-KIDNEY). Entretanto, se ha puesto en marcha el estudio de fase III DOUBLE PROTECT Alport (NCT05944016), en el que se eval\u00faan la eficacia y la seguridad de los inhibidores de SGLT2 como tratamiento complementario al tratamiento est\u00e1ndar en pacientes de entre 10 y 40 a\u00f1os con ERC de origen gen\u00e9tico (s\u00edndrome de Alport).<\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Fla-dapagliflozina-un-inhibidor-de-la-sglt-2-como-tratamiento-complementario-al-bloqueo-del-sra%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>El amplio espectro de efectos terap\u00e9uticos de los inhibidores de SGLT-2 (cotransportador de sodio-glucosa tipo 2) abarca, entre otros, la protecci\u00f3n cardiorrenal en pacientes con enfermedad renal cr\u00f3nica (ERC) no&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Fla-dapagliflozina-un-inhibidor-de-la-sglt-2-como-tratamiento-complementario-al-bloqueo-del-sra%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":565852,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Enfermedad renal de origen gen\u00e9tico: DOUBLE PROTECT Alport","footnotes":"[{\"content\":\"<em>tasa de filtraci\\u00f3n glomerular estimada (TFGe) >60 ml\\\/min\\\/1,73 m\\u00b2;<\\\/em>\",\"id\":\"de281f80-e833-44d8-8f97-4476b5bc7e6c\"},{\"content\":\"<em>En lo que respecta a la canagliflozina, que tambi\\u00e9n es un inhibidor de SGLT-2, la autorizaci\\u00f3n de Swissmedic se limita actualmente a la nefropat\\u00eda diab\\u00e9tica en adultos (informaci\\u00f3n actualizada a 3 de septiembre de 2026).<\\\/em>\",\"id\":\"6d28f7e2-6362-4781-bb54-2555ce6ea639\"}]","_members_access_role":[],"_members_access_error":""},"category":[11552,11475,11478,11364,11288,11377],"tags":[100934,23370,66558,23317,100932,21539,100933,13023,24272,100936,71833,100938],"powerkit_post_featured":[],"class_list":["post-565847","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-es","category-estudios","category-formacion-continua","category-genetica","category-medicina-interna-general","category-nefrologia","tag-bloqueo-del-ras","tag-complemento","tag-dapa-ckd-es","tag-dapagliflozina","tag-double-protect-alport","tag-enfermedad-renal","tag-ent-de-origen-genetico","tag-erc","tag-inhibidor-sglt-2","tag-nct05944016","tag-proteccion-cardiorrenal","tag-terapia-complementaria-2","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-10-05 02:35:01","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"es_ES","wpml_translations":[],"_links":{"self":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/565847","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/comments?post=565847"}],"version-history":[{"count":2,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/565847\/revisions"}],"predecessor-version":[{"id":568599,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/565847\/revisions\/568599"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media\/565852"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media?parent=565847"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/category?post=565847"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/tags?post=565847"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/powerkit_post_featured?post=565847"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}